Zura Bio (NASDAQ:ZURA) Trading Down 7.9% – Should You Sell?

Zura Bio Limited (NASDAQ:ZURA)’s share price traded down 7.9% during trading on Wednesday . The company traded as low as $5.51 and last traded at $5.4310. Approximately 142,710 shares traded hands during trading, a decline of 83% from the average session volume of 831,630 shares. The stock had previously closed at $5.90.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ZURA. Wedbush reaffirmed an “outperform” rating and set a $15.00 price target on shares of Zura Bio in a research note on Wednesday. Oppenheimer reduced their price objective on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday, March 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. Finally, Chardan Capital lifted their target price on shares of Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Zura Bio currently has a consensus rating of “Moderate Buy” and an average price target of $10.75.

Zura Bio Trading Down 12.8%

The stock has a market capitalization of $488.16 million, a price-to-earnings ratio of -4.76 and a beta of 0.03. The business has a 50 day simple moving average of $4.47 and a 200-day simple moving average of $5.29.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). Research analysts predict that Zura Bio Limited will post -0.76 EPS for the current year.

Hedge Funds Weigh In On Zura Bio

A number of hedge funds have recently made changes to their positions in the stock. Allworth Financial LP purchased a new stake in shares of Zura Bio during the 4th quarter valued at $30,000. Scientech Research LLC purchased a new stake in Zura Bio during the third quarter valued at about $45,000. AQR Capital Management LLC acquired a new stake in Zura Bio during the first quarter worth about $72,000. Bank of America Corp DE raised its holdings in shares of Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in shares of Zura Bio in the 3rd quarter worth about $109,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.